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Abstract
Purpose A tert-leucinate derivative synthetic cannabinoid, methyl (2S)-2-([1-(4-fluorobutyl)-1H-indazole-3-carbonyl]
amino)-3,3-dimethylbutanoate (4F-MDMB-BINACA, 4F-MDMB-BUTINACA or 4F-ADB) is known to adversely impact 
health. This study aimed to evaluate the suitability of three different modes of monitoring metabolism: HepG2 liver cells, 
fungus Cunninghamella elegans (C. elegans) and pooled human liver microsomes (HLM) for comparison with human in-
vivo metabolism in identifying suitable urinary marker(s) for 4F-MDMB-BINACA intake.
Methods Tentative structure elucidation of in-vitro metabolites was performed on HepG2, C. elegans and HLM using liquid 
chromatography–tandem mass spectrometry and high-resolution mass spectrometry analysis. In-vivo metabolites obtained 
from twenty authentic human urine samples were analysed using liquid chromatography–Orbitrap mass spectrometry.
Results Incubation with HepG2, C. elegans and HLM yielded nine, twenty-three and seventeen metabolites of 4F-MDMB-
BINACA, respectively, formed via ester hydrolysis, hydroxylation, carboxylation, dehydrogenation, oxidative defluorination, 
carbonylation or reaction combinations. Phase II metabolites of glucosidation and sulfation were also exclusively identified 
using C. elegans model. Eight in-vivo metabolites tentatively identified were mainly products of ester hydrolysis with or 
without additional dehydrogenation, N-dealkylation, monohydroxylation and oxidative defluorination with further oxidation 
to butanoic acid. Metabolites with intact terminal methyl ester moiety, i.e., oxidative defluorination with further oxidation 
to butanoic acid, were also tentatively identified.
Conclusions The in-vitro models presented proved useful in the exhaustive metabolism studies. Despite limitations, HepG2 
identified the major 4F-MDMB-BINACA ester hydrolysis metabolite, and C. elegans demonstrated the capacity to produce 
a wide variety of metabolites. Both C. elegans and HLM produced all the in-vivo metabolites. Ester hydrolysis and ester 
hydrolysis plus dehydrogenation 4F-MDMB-BINACA metabolites were recommended as urinary markers for 4F-MDMB-
BINACA intake.
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Introduction
Synthetic cannabinoids (SCBs) are agonists at cannabi-
noid receptor type 1  (CB1) and type 2  (CB2), where they 
elicit their main effects. Due to their similar physiological 
effects to the principal psychoactive component of can-
nabis, Δ9-tetrahydrocannabinol (THC), SCBs are gaining 
popularity and are often abused as recreational drugs. 
However, most of the SCBs are full agonists at  CB1 and 
 CB2 receptors, having a higher risk of undesirable side 
effects when compared to THC which is a partial ago-
nist [1]. Methyl (2S)-2-([1-(4-fluorobutyl)-1H-indazole-
3-carbonyl]amino)-3,3-dimethylbutanoate (4F-MDMB-
BINACA, 4F-MDMB-BUTINACA or 4F-ADB), found 
in numerous SCB product seizures, has been reported by 
various law enforcement since 2018 [2]. The tert-leucine 
derived indazole-3-carboxamide analog 4F-MDMB-
BINACA postulated to be a potent agonist of the  CB1 
receptor based upon its structural similarity to methyl-
2-([1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino)-
3,3-dimethylbutanoate (5F-MDMB-PINACA) [3, 4], has 
significant abuse potential and causes central nervous sys-
tem depression. Death involving these drugs have been 
reported [5–9], and this raises public health and social 
concerns. Moreover, 4F-MDMB-BINACA has been listed 
in Schedule II of the Convention on Psychotropic Sub-
stances of 1971 recently.
The proliferation of SCBs has become a global chal-
lenge as new compounds are rapidly introduced into the 
illegal drug market to evade existing drug laws. Identify-
ing SCB intake and its correlating specific adverse effects 
require rapid elucidation of these SCBs. Since most SCBs 
are found extensively in metabolized forms in urine, the 
identification of metabolites is of vital importance for 
forensic and clinical toxicologists. Furthermore, some 
hydroxylated urinary metabolites have been found to be 
active and more toxic than the parent SCBs themselves, 
emphasizing the importance of metabolism study in iden-
tifying potential toxic metabolites [10, 11].
Traditional in-vivo metabolism studies to generate 
human metabolites of drugs relied heavily on the use of 
whole animal model systems, which are expensive, limited 
by drug administration amount, influenced by species vari-
ation and faced by many ethical issues. In-vitro metabo-
lism studies are generally used to complement these data 
using perfused organs, tissue or cell cultures and micro-
somal preparations amongst which pooled human liver 
microsomes (HLM) have been frequently used to elucidate 
metabolism of SCBs [12–16]. The hepatic cell line HepG2 
is often used as an initial screen as it is known to produce 
high reproducibility results with relatively stable enzyme 
concentration, although they are limited by the low-level 
expression of several metabolizing enzymes, including 
the cytochrome P450 (CYP) class of proteins [17, 18]. 
The metabolic competence of HepG2 was described to be 
sufficient for in-vitro studies after an incubation time of 
at least 72 h [19]. An alternative to this was the use of a 
microbial model with phase I and II metabolite-generating 
capabilities such as the zygomycete fungus, Cunningha-
mella elegans (C. elegans). C. elegans has the advantage 
of more closely mimicking mammalian metabolism [20] 
and has been used as a complementary model in metabo-
lism studies of new psychoactive substances, in particular, 
the SCBs [21–26]. This class of fungi has an enzymatic 
activity to facilitate phase I and II metabolism includ-
ing hydroxylation, carboxylation, dihydrodiol formation, 
oxidative defluorination, N-dealkylation, glucuronida-
tion, glucosidation, and sulfation [23, 27]. The advan-
tages offered by the microbial transformation over other 
approaches include the low setting up cost, reliability and 
reproducibility as well as possible economical scale-up 
affording both phase I and II metabolites in higher yield. 
This scaled production is useful for further characteriza-
tion of metabolites that are required to be distinguished 
from its isomeric species and in the identification of poten-
tially toxic metabolites [28].
Although there were reports on the metabolism of 
4F-MDMB-BINACA using in-vivo and various in-vitro 
models, studies were either conducted using small in-vivo 
sample size such as 1 to 4 samples [5, 29] or in closed envi-
ronments such as forensic psychiatric wards and prisons 
[30]. In our study, twenty in-vivo urine samples screened 
positive for 4F-MDMB-BINACA intake were employed and 
the findings were compared to those obtained via HepG2, 
C. elegans, and HLM in-vitro models. The aim of this study 
was to assess the suitability of these in-vitro models in the 
in-vitro − in-vivo extrapolations and to suggest suitable uri-
nary marker(s) for 4F-MDMB-BINACA intake.
Materials and methods
Chemicals and reagents
4F-MDMB-BINACA was provided by Health Sciences 
Authority (Singapore). 4F-MDMB-BINACA 3,3-dimeth-
ylbutanoic acid metabolite was purchased from Cayman 
Chemical (Ann Arbor, MI, USA). In-vitro metabolism 
study: one hundred fifty (mixed gender) - donor HLM pool, 
NADPH system solution A and NADPH system solution 
B, T75 tissue culture flasks, and 96‐well cell culture plates 
were purchased from Corning (Corning, NY, USA); C. ele-
gans ATCC 10028b from Cryosite Ltd. (South Granville, 
NSW, Australia); HepG2 cell line from CellBank (Sydney, 
NSW, Australia). Minimum Essential Medium - Eagle with 
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Earle’s BSS (MEM Eagle with EBSS) from Lonza (Basel, 
Switzerland); liquid chromatography − mass spectrome-
try (LC–MS) grade acetonitrile (ACN) from Honeywell 
(Muskegon, MI, USA); reagent grade dichloromethane 
 (CH2Cl2) and sodium chloride (NaCl) from Chem-Supply 
(Gilman, SA, Australia); LC–MS grade formic acid from 
Sigma-Aldrich (St. Louis, MO, USA); glycerol, potassium 
dihydrogen phosphate  (KH2PO4) and dipotassium hydro-
gen phosphate  (K2HPO4) from Ajax Chemicals (Auburn, 
NSW, Australia); potato dextrose agar, glucose, peptone, 
and yeast extract from Oxoid Australia (Adelaide, SA, 
Australia). In-vivo metabolism study: chemicals for pre-
paring reagents and buffers were obtained from Fluka, 
Sigma-Aldrich (St. Louis, MO, USA). Optima LC–MS 
grade ACN from ThermoFisher Scientific (Fair Lawn, 
NJ, USA); purified water was used, and all solvents used 
were of LC–MS grade or better; β-glucuronidase from 
abalone (Haliotis rufescens) from KURA Biotec (Rancho 
Dominguez, CA, USA); Clean Screen FASt® filter tubes 
(3 mL packed with 200 mg solid-phase sorbent) from 
UCT, Inc (Bristol, PA, USA).
Monitoring in‑vitro metabolism
HepG2 liver cells
Cryofrozen HepG2 cells were thawed and subcultured 
(up to passage 7) in a T75 tissue culture flask containing 
MEM Eagle with EBSS media supplemented with 10% 
heat‐inactivated fetal bovine serum (HI‐FBS), l‐glutamine 
(2 mM), penicillin:streptomycin (100 U/mL:100 μg/mL) 
and non‐essential amino acid solution (NEAA, 1x). The 
cells were cultured at 37 °C in a humidified atmosphere 
incubator containing 95% air and 5%  CO2, until ~ 80% con-
fluent. The media was changed every 2 days, and when 
required, cells were harvested by subculture with media 
containing trypsin/EDTA (0.12% trypsin/ 0.02% EDTA, 
w/v). The following method was adopted [31] with slight 
modifications: cells were seeded at a density of 9600 cells/
well onto 96‐well plates overnight. Cells were treated with 
120 μM of 4F-MDMB-BINACA media solution (100 μL) 
in triplicates for 72 h. The supernatant (60 μL) was trans-
ferred into a 0.5 mL capped tube containing ice-cold ACN 
(60 μL). The mixture was vortex-mixed and cooled for 
another 15 min at  – 30 °C before centrifuging at 10,000 g 
for 5 min. The filtered sample (0.22 µm, 100 μL) was 
diluted with ACN (500 μL) and 10 µL was subjected  to 
liquid chromatography − quadrupole time-of-flight mass 
spectrometry (LC − QTOF-MS). A 2 µL aliquot was also 
subjected to liquid chromatography–triple quadrupole-
mass spectrometry (LC − QQQ-MS). A control without 
HepG2 and/or without 4F-MDMB-BINACA were also 
treated in the identical fashion.
Fungus C. elegans
C. elegans was cultured on potato dextrose agar plates at 
27 °C for 5 days. The mycelia of the fungus were mixed 
in sterile physiological saline solution (1 plate of myce-
lia/10 mL). Growth medium consisting of NaCl/KH2PO4/
yeast extract/peptone/glucose (1:1:1:1:2, v/v/v/v/v), water 
and glycerol was prepared as previously described [32] and 
autoclaved (121 °C, 15 min) before use. A 1.5-mL volume 
of the homogenate was inoculated into 100 mL of growth 
medium in a conical flask. The culture was incubated for 
48 h at 26 °C and 180 rpm on a Multitron rotary shaker 
(Infors AG, Bottmingen, Switzerland). 4F-MDMB-BIN-
ACA (1 mg in 0.5 mL ACN) was added to the conical flask 
in triplicate and incubated for another 72 h. The solution 
was filtered in a Buchner funnel, extracted with  CH2Cl2 
(3 × 50 mL). The combined extracts were evaporated to dry-
ness using a rotary evaporator followed by a vacuum pump. 
The sample was reconstituted in 2 mL ACN and filtered 
using a 0.22 µm filter and was further diluted in ACN ten-
fold before injected (5 µL) into the LC − QTOF-MS instru-
ment. An aliquot of the filtrate (100 µL) was diluted in 900 
µL water/ACN (90:10, v/v) and 2 µL was also injected into 
the  LC − QQQ-MS  instrument. Control samples in the 
absence of C. elegans and/or 4F-MDMB-BINACA were 
also treated in the identical fashion.
Pooled human liver microsomes 
The incubation mixture using 4F-MDMB-BINACA solution 
in ACN/phosphate buffer (25 µL, final concentration 1.7 µM 
in 0.03% ACN), phosphate buffer (0.1 M, pH 7.4, 855 µL), 
NADPH-A (50 µL) and NADPH-B (20 µL) was mixed in a 
2 mL capped tube, to which HLM (50 µL = 1 mg protein) 
was added. The mixture was vortexed mixed and incubated 
in triplicate at 37 °C in a shaking water bath (100 rpm) for 
1 h. The reaction was quenched by adding ice-cold ACN 
(1 mL) to the mixture, vortex mixed and then centrifuged 
at 13,000 g for 10 min. The sample was filtered (0.22 µm) 
and 5 µL was injected into the LC − QTOF-MS  instru-
ment. A 100-µL volume of the filtrate was diluted in 900 
µL water/ACN (90:10, v/v), and 2 µL was also injected 
into the LC − QQQ-MS instrument. Controls samples with-
out HLM and/or without 4F-MDMB-BINACA were also 
incubated and subsequently worked up under the identical 
conditions.
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LC − QTOF‑MS
Chromatographic separation was performed on an Agilent 
1290 LC system with a Poroshell 120 EC-C18 analytical 
column (2.7 μm, 75 × 2.1 mm; Agilent Technologies, Santa 
Clara, CA, USA). The mobile phase consisted of 0.1% 
formic acid in water (A) and 0.1% formic acid in acetoni-
trile (B). The gradient elution was as follows: 10% B until 
2 min, increased to 40% B until 4 min, ramped to 60% B 
until 15 min, and further increased to 80% B at 18 min and 
ramped down to 10% B until 19 min and held until 21 min. 
The flow rate was 0.3 mL/min and the column temperature 
was kept at 35 °C. High-resolution QTOF-MS data were 
acquired on an Agilent 6510 Accurate Mass QTOF mass 
spectrometer (Agilent Technologies) equipped with dual 
electrospray ionization (ESI) source operated in both posi-
tive and negative ion modes, to determine accurate masses 
of the metabolites. The parameters were as follows: scan-
ning mass range, m/z 100–700 (MS), m/z 100–600 (MS/
MS); capillary voltage, 3500 V; nebulizer pressure, 40 psi; 
gas temperature, 310 °C; drying gas flow, 13 L/ min; frag-
mentor voltage, 160 V; collision energy (CE) for product 
ion scan analysis, 10, 20 and 40 eV; skimmer voltage, 65 V. 
Mass calibration was performed with the mixture provided 
by the manufacturer. Real-time mass calibration was ena-
bled using the following reference masses: m/z 118.086255 
and 322.048121 (positive ion mode); 112.985587 and 
301.998139 (negative ion mode). Extracted ion chromato-
grams and product ion spectra were analysed using Agilent 
MassHunter Workstation Software Qualitative Analysis 
(version B.06.00). The criteria for metabolites elucidation 
were as follows: mass error of the precursor ion ≤ 5.00 ppm, 
mass error of product ions ≤ 20.00 ppm, consistent fragmen-
tation pattern with the proposed structure, reasonable reten-
tion time, and absence of the specific peak in controls.
LC − QQQ‑MS
Chromatographic equipment and conditions were the same 
as described above. MS was run in multiple reaction moni-
toring (MRM) mode on an Agilent 6490 Triple Quadrupole 
mass spectrometer with ESI source in positive ion mode 
(Agilent Technologies). An optimised CE 8–40 eV was 
applied for each individual MRM transition. The source 
parameters were as follows: the capillary and nozzle volt-
ages, 3500 and 1500 V, respectively; the sheath gas tem-
perature and flow set to 400 °C and 12 L/min, respectively; 
nebulizer pressure, 40 psi; gas temperature, 290 °C; drying 
gas flow, 12 L/min; fragmentor voltage, 380 V. Mass calibra-
tion was routinely performed via check tune before analysis. 
Extracted ion chromatograms and MRM mass chromato-
grams were analysed using Agilent MassHunter Workstation 
Software Qualitative Analysis (version B.06.00). Percentage 
(%) peak area ratio was obtained by dividing the peak area of 
the detected metabolite by the peak area of the most abun-
dant metabolite in the same sample. Major metabolites were 
defined as those with greater than 10% average peak area 
ratios.
In‑vivo metabolism
Authentic human urine samples
Antemortem urine samples from routine toxicology cases 
(n = 20) confirmed with the 4F-MDMB-BINACA ester 
hydrolysis metabolite (4F-MDMB-BINACA 3,3-dimeth-
ylbutanoic acid metabolite) were processed and analysed 
for in-vivo metabolites in collaboration with the in-vitro 
metabolism findings. Urine sample (500 µL) was incu-
bated with 250 µL of pH 5 acetate buffer (1 M) and 50 µL 
β-glucuronidase (10,000 Fisherman units/mL) for 1 h at 
60 °C. After incubation, the mixture was cooled at room 
temperature, and 150 µL of purified water was added. The 
mixture was vortex-mixed and 500 µL of this mixture and 
500 µL of methanol were loaded onto the Clean Screen 
FASt® tube. About 10–20 bar pressure was applied on the 
tube using a positive pressure manifold to allow all the sam-
ples to flow through the tube. The eluent was collected in a 
2 mL sample vial for analysis.
LC − Orbitrap‑MS
Chromatographic separation was achieved on a Kinetex 
XB-C18 column (2.6 µm, 100 × 2.1 mm; Phenomenex, Tor-
rance, CA, USA) with an identically packed defender guard 
cartridge (2.6 µm, 10 × 2.1 mm). The mobile phase consisted 
of 10 mM ammonium formate, pH 3 (A) and 0.1% formic 
acid in ACN (B). The gradient elution was as follows: 5% B 
until 1 min, increased to 95% B until 10 min, ramped to 99% 
B at 10.1 min, held until 11.5 min, ramped down to 5% B at 
11.6 min and held until 13.0 min. The flow rate was 0.5 mL/
min for the whole run except from 10.1 to 11.5 min which 
was set at 0.8 mL/min. The identification of the metabolites 
was performed using liquid chromatography coupled with 
Thermo Scientific Q-Exactive hybrid quadrupole - Orbitrap 
mass spectrometer (Thermo Scientific, Fremont, CA, USA) 
equipped with heated electrospray ionization source (HESI-
II) operated in positive ionization with full MS and data-
dependent  MS2 acquisition mode. The parameters were as 
follows: scanning mass range, m/z 120–1000 (MS); sheath 
gas, 40 arbitrary units (AU); auxiliary gas, 10 AU; sweep 
gas, 1 AU; spray voltage, 3.5 kV; capillary temperature, 
270 °C; heater temperature, 425 °C. The in-vitro metabolites 
elucidated from the cultured HepG2 cells, C. elegans and 
HLM were added to the compound database. Data obtained 
from the twenty urine samples were retrospectively analysed 
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and processed using TraceFinder software based on the iden-
tification criteria of mass errors less than ± 5 ppm for full 
MS peaks and MS/MS peaks from the theoretical mass and 
matching of MS/MS spectra. Percentage (%) peak area ratios 
of the metabolites were similarly calculated as the in-vitro 
metabolism study.
Results
A total of 25 different metabolites (B1–B25) was tentatively 
identified and listed in Table 1 in the order of retention 
time (RT) with postulated biotransformation. 4F-MDMB-
BINACA was eluted at 12.0 min, whilst the metabolites 
eluted between 5.3 and 9.6 min. Metabolites were identified 
according to their precursor ions, product ions, and frag-
mentation patterns (Fig. 1). The proposed biotransformation 
pathways of 4F-MDMB-BINACA are presented in Fig. 2.
In‑vitro metabolism
Twenty-three, seventeen and nine metabolites were tenta-
tively identified after incubation of 4F-MDMB-BINACA 
with C. elegans, HLM and HepG2 cells, respectively.
Ester hydrolysis of 4F-MDMB-BINACA gener-
ated 4F-MDMB-BINACA ester hydrolysis metabolite, 
4F-MDMB-BINACA 3,3-dimethylbutanoic acid (B22) 
with further dehydrogenation (B20), monohydroxylation 
(B8, B9, B13) with further dehydrogenation (B5/B6, B14), 
oxidative defluorination (B2) with subsequent oxidation to 
butanoic acid (B4) and N-dealkylation (B1). Other metab-
olites retained the terminal methyl ester moiety and their 
biotransformation tentatively identified included: monohy-
droxylation (B19/B21, B23/B25) with further carbonylation 
(B24), dihydroxylation (B10, B12/B15), oxidative defluori-
nation (B18) and further oxidation to butanoic acid (B17) 
and N-dealkylation (B16). Phase II glucosidation (B7) and 
Table 1  In-vitro metabolites of 4F-MDMB-BINACA tentatively identified using Cunninghamella. elegans (C. elegans)(F), human liver micro-
somes (HLM)(M) and HepG2 (H) models
Mass error of the precursor ion ≤ 5.00 ppm and mass error of product ions ≤ 20.00 ppm
ID identity, RT retention time, U in-vivo urine sample
ID RT (min) Biotransformation Formula Exact mass [M + H]+ U F M H
B1 5.30 Ester hydrolysis, N-dealkylation C14H17N3O3 276.1343 ✔ ✔ ✔ ✔
B2 5.40 Ester hydrolysis, oxidative defluorination C18H25N3O4 348.1918 ✔ ✔ ✔ ✔
B3 5.40 Ester hydrolysis, oxidative defluorination to butanoic acid, dehy-
drogenation
C18H21N3O5 360.1550 ✔
B4 5.45 Ester hydrolysis, oxidative defluorination to butanoic acid C18H23N3O5 362.1710 ✔ ✔ ✔
B5 5.50 Ester hydrolysis, monohydroxylation (butyl), dehydrogenation C18H22FN3O4 364.1667 ✔
B6 5.70 Ester hydrolysis, monohydroxylation (butyl), dehydrogenation C18H22FN3O4 364.1667 ✔ ✔
B7 5.80 Monohydroxylation (indazole), glucosidation C25H36FN3O9 542.2508 ✔
B8 5.85 Ester hydrolysis, monohydroxylation (tert-leucine) C18H24FN3O4 366.1824 ✔ ✔ ✔ ✔
B9 6.10 Ester hydrolysis, monohydroxylation (butyl) C18H24FN3O4 366.1824 ✔ ✔
B10 6.10 Dihydroxylation (butyl) C19H26FN3O5 396.1929 ✔
B11 6.40 Monohydroxylation (indazole), sulfation C19H26FSN3O7 460.1548 ✔
B12 6.60 Dihydroxylation (indazole, butyl) C19H26FN3O5 396.1929 ✔
B13 6.70 Ester hydrolysis, monohydroxylation (indazole) C18H24FN3O4 366.1824 ✔ ✔ ✔
B14 6.75 Ester hydrolysis, monohydroxylation (tert-leucine), dehydrogena-
tion
C18H22FN3O4 364.1667 ✔ ✔
B15 6.90 Dihydroxylation (indazole, butyl) C19H26FN3O5 396.1929 ✔
B16 7.10 N-Dealkylation C15H19N3O3 290.1499 ✔ ✔ ✔
B17 7.30 Oxidative defluorination to butanoic acid C19H25N3O5 376.1867 ✔ ✔ ✔ ✔
B18 7.35 Oxidative defluorination C19H27N3O4 362.2074 ✔ ✔ ✔ ✔
B19 7.70 Monohydroxylation (butyl) C19H26FN3O4 380.1980 ✔ ✔
B20 7.90 Ester hydrolysis, dehydrogenation C18H22FN3O3 348.1718 ✔ ✔ ✔ ✔
B21 8.10 Monohydroxylation (butyl) C19H26FN3O4 380.1980 ✔ ✔
B22 8.30 Ester hydrolysis C18H24FN3O3 350.1874 ✔ ✔ ✔ ✔
B23 8.50 Monohydroxylation (indazole) C19H26FN3O4 380.1980 ✔
B24 9.00 Carbonylation C19H24FN3O4 378.1824 ✔
B25 9.60 Monohydroxylation (indazole) C19H26FN3O4 380.1980 ✔
B0 12.00 4F-MDMB-BINACA C19H26FN3O3 364.2031 ✔ ✔ ✔
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Fig. 1  Product ion spectra and tentative structures with the suggested 
fragmentation patterns from the three in-vitro models: Cunningha-
mella elegans (C. elegans)(F), human liver microsomes (HLM)(M) 
and HepG2 (H). The brackets indicate product ion  spectra obtained 
from one of the in-vitro model with collision energy 10 or 20 eV. The 
exact position of the hydroxylation was not determined
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sulfation (B11) metabolites were only detected in the C. 
elegans model. The tentative structure elucidation of these 
various metabolites from the different models examined was 
constructed and shown below.
Phase I  biotransformation
Ester hydrolysis, dehydrogenation, hydroxylation, 
oxidation and dealkylation
All the below explanations for transformations into metabo-
lites are based on the data shown in Fig. 1 and on probable 
metabolic pathways shown in Fig. 2. 4F-MDMB-BINACA 
was hydrolysed via ester hydrolysis forming the 4F-MDMB-
BINACA ester hydrolysis metabolite (B22). The product ion 
Fig. 1  (continued)
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spectrum was very similar to 4F-MDMB-BINACA (m/z 304, 
219, 145). The precursor ion, m/z 350 showed a loss of 14 Da 
explaining the hydrolysis of methyl ester from 4F-MDMB-
BINACA. B20 showed a similar product ion fragmentation 
pattern to that of B22 (m/z, 219, 145) and additional loss of 
2 Da from m/z 350, indicating ester hydrolysis and further 
dehydrogenation at the tert-leucine moiety.
Metabolites identified at m/z 366 (B8, B9, B13), which 
was 16  Da higher than the 4F-MDMB-BINACA ester 
hydrolysis metabolite (B22), confirmed monohydroxylation 
upon ester hydrolysis. The presence of the product ion m/z 
320, likely formed from a loss of carbon dioxide, indicated 
monohydroxylation at the tert-leucine in B8 (m/z 219), butyl 
side chain in B9 (m/z 145) and indazole moiety in B13 (m/z 
161). The precursor ion, m/z 364 (B14, B5/B6) had a loss of 
2 Da from m/z 366 indicated further dehydrogenation of the 
ester hydrolysis plus monohydroxylated metabolites. Dehy-
drogenation occurred at the tert-leucine moieties for both the 
monohydroxylated metabolites (B5/B6, B14), indicated by 
the presence of product ions m/z 235/346 and m/z 219/346, 
respectively. Similarly, precursor ion identified at m/z 380 
(B19/B21, B23/B25) was 16 Da higher than the 4F-MDMB-
BINACA, indicating monohydroxylation at the butyl side 
chain (B19/B21) and indazole (B23/B25) moieties with 
product ions m/z 145 and 161, respectively. The metabolite 
(B24) identified at m/z 378 had very similar product ion 
spectra with B19/B21 except it was 2 Da lower (equating 
to the loss of 2 hydrogen atoms) while retaining the same 
product ion m/z 145, indicating  carbonylation at the butyl 
side chain moiety.
The precursor ion m/z 396 (B10, B12/B15) was 32 Da 
higher than the parent drug, 4F-MDMB-BINACA, sug-
gesting the addition of two hydroxy groups. The product 
ion m/z 336 (loss of methyl ester moiety) further confirmed 
the presence of dihydroxylated metabolites. The presence 
of product ion m/z 251 at B10 and B12/B15 was explained 
by noting that hydroxylation occurred at the indazole/butyl 
side chain moieties and not at the tert-leucine moiety. B10 
showed product ion m/z 145 indicating intact indazole 
moiety and suggested that dihydroxylation occurred at the 
butyl side chain moiety. The presence of product ion m/z 
161 in B12/B15, indicated that hydroxylation occurred at 
the indazole moiety, whilst the second hydroxylation site 
must be assigned at the butyl side chain moiety. 
The precursor ion m/z 348 and product ion detected at 
m/z 217 (B2) identified was 2 Da less than the 4F-MDMB-
BINACA ester hydrolysis metabolite (B22), indicating 
oxidative defluorination (loss of fluorine with addition of 
hydroxy group). Product ions detected at m/z 302, 217, and 
145 (B2) confirmed that tert-leucine and indazole moie-
ties remained unchanged, leading to the structure elucida-
tion of a hydroxy-functional group at the 4-position of the 
butyl side chain by oxidative defluorination. Oxidation of 
4′-hydroxybutyl moiety in B2 led to formation of 4′-car-
boxybutyl metabolite (B4) having a precursor ion of m/z 
362, which was 14 Da higher than the m/z for B2 (loss of 
two hydrogen atoms with addition of a carbonyl group). 
Fig. 2  Proposed metabolic pathways of 4F-MDMB-BINACA. In-vivo metabolites were in italics and bold. The exact position of the hydroxyl 
moiety of the metabolites was not determined
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The precursor ion m/z 360 and product ion detected at 
m/z 342 (B3) identified was 2 Da less than precursor ion 
at m/z 362 (B4) indicated further dehydrogenation at the 
tert-leucine moiety.
The precursor ion m/z 276 (B1) detected, which was 
74 Da lower than that for the 4F-MDMB-BINACA ester 
hydrolysis metabolite (B22), indicated N-dealkylation 
of B22. The product ion of B1 detected at m/z 230 was 
assigned as a neutral loss of HCOOH.
N‑Dealkylation
The precursor ion m/z 290 (B16) which was 74 Da lower 
than the corresponding m/z for 4F-MDMB-BINACA, 
indicated N-dealkylation of 4F-MDMB-BINACA. Prod-
uct ions m/z 258, 230 and 145 showed loss of a single 
methoxy group, methyl ester and indazole carbonyl frag-
ment, respectively. Taken together these data further con-
firmed the structure elucidation of B16.
Oxidative defluorination and oxidation
Metabolite B18 with precursor ion at m/z 362 and product 
ions at m/z 330, 302, 217 were consecutively 2 Da less 
than that of the precursor and product ions of 4F-MDMB-
BINACA, being indicative of oxidative defluorination. 
Further oxidation of 4′-hydroxybutyl moiety of B18 
resulted in 4′-carboxybutyl, B17 (m/z 376) having product 
ions m/z 316, 231 and 213. The product ions  at m/z 316 
and 231 in B17 were 14 Da higher than that of product 
ions 302 and 217, respectively, in B18, consistent with 
the formation of a butanoic acid metabolite.
Phase II biotransformation
Glucosidation
Precursor ion, m/z 542 (B7) resulted from glucosidation 
of B23/B25. Both have product ions m/z 320, 235 and 
161. The product ion detected at m/z 380 was produced 
by neutral loss of 162 Da (glucoside).
Sulfation
Precursor ion, m/z 460 (B11) detected was a result of sul-
fation of intermediate metabolite similar to B23/B25. The 
product ion detected at m/z 235, indicating loss of sulfate, 
confirmed the identity of the sulfation metabolite.
Comparison among the in‑vitro models
The major in-vitro phase I metabolites (> 10% peak area 
ratio) tentatively identified were monohydroxylation at the 
butyl side chain and oxidative defluorination to butanoic 
acid for the C. elegans model. HLM model produced four 
major metabolites: ester hydrolysis with/without dehydro-
genation, monohydroxylation at indazole moiety and oxi-
dative defluorination. HepG2 model only produced one 
major metabolite (B22) which was the ester hydrolysis of 
4F-MDMB-BINACA (Table 2). Although the metabolite 
ranking may differ in all the three models, four common 
metabolites amongst the seven most abundant metabolites 
were identified (Fig. 3 a–d): ester hydrolysis (B22, m/z 350), 
ester hydrolysis followed by dehydrogenation (B20, m/z 
348), oxidative defluorination (B18, m/z 362) and further 
oxidation to butanoic acid (B17, m/z 376).
Table 2  Comparison of the in-vitro metabolites from the three models (n = 3) with the in-vivo metabolites obtained from authentic human urine 
samples (n = 20)
Major in-vitro metabolites (not less than 10% peak area ratio) are in italic and bold
ND not detected
ID Biotransformation In-vivo metabolites % peak 
area ratio (sample size)
In-vitro metabolites % peak area 
ratio
C. elegans HLM HepG2
B22 Ester hydrolysis 100 (20/20) 2.3 100 100
B20 Ester hydrolysis, dehydrogenation 1.7–9.4 (18/20) 3.8 70 1.4
B4 Ester hydrolysis, oxidative defluorination to butanoic acid 1.5–27 (16/20) 0.016 0.25 ND
B8 Ester hydrolysis, monohydroxylation (tert-leucine) 3.7–14 (16/20) 0.067   1.9 0.14
B1 Ester hydrolysis,  N-dealkylation 0.65–29 (15/20) 0.003 0.73 6.4
B18 Oxidative defluorination 1.4–5.4 (13/20) 2.1  10 1.0
B2 Ester hydrolysis, oxidative defluorination 2.0–11 (12/20) 0.005 0.67 1.5
B17 Oxidative defluorination to butanoic acid 0.26–1.4 (7/20) 76 8.9  0.57
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In‑vivo metabolism
A total of eight metabolites were detected in the analysed 
human urine samples (Tables 2, 3). The average % peak area 
ratio of the urine metabolites from twenty urine samples 
were tabulated and compared to that of the in-vitro metabo-
lites (Table 2).
Ester hydrolysis biotransformation constituted the domi-
nant metabolic pathway for the in-vivo metabolism in human 
urine samples. The prevalence of the tentatively identified 
metabolites was as follows: 4F-MDMB-BINACA ester 
hydrolysis metabolite (B22, m/z 350, 20/20 samples) fol-
lowed by further dehydrogenation (B20, m/z 348, 18/20 sam-
ples). Both ester hydrolysis followed by oxidative defluorina-
tion to butanoic acid (B4, m/z 362) and monohydroxylation 
at tert-leucine moiety (B8, m/z 366) metabolites were found 
in 16/20 urine samples (Table 2). Ester hydrolysis followed 
with N-dealkylation (B1, m/z 276) metabolite was found in 
15/20 urine samples. Oxidative defluorination (B18, m/z 
362) and ester hydrolysis of oxidative defluorination (B2, 
m/z 348) metabolites were detected in 13/20 and 12/20 urine 
samples, respectively. Oxidative defluorination to butanoic 
acid metabolite (B17, m/z 376) was detected in the least 
number of urine samples (7/20 samples). Only 3/20 urine 
samples were identified with the parent drug, 4F-MDMB-
BINACA, highlighting the risk of analysing only parent ions 
and emphasizing the importance of metabolite identification 
in the forensic and clinical setting. The metabolite ranking 
was different for different individual urine samples.
The analysed urine samples (17/20 samples) 
were also detected with other SCBs such as methyl 
2 - ( [ 1 - ( 5 - f l u o r o p e n t y l ) - 1 H - i n d o l e - 3 - c a r b o nyl ]
Fig. 3  a In-vitro metabo-
lites observed in com-
mon among  respective seven 
most abundant metabolites in 
b C. elegans, c HLM and d 
HepG2 models. C. elegans, 
HLM and HepG2 are repre-
sented by horizontal, diagonal 
and vertical bar lines, respec-
tively. Error bars reflect the 
relative abundance variation of 
a specific metabolite within the 
analysed group (n = 3)
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amino)-3,3-dimethylbutanoate (5F-MDMB-PICA), methyl 
3,3-dimethyl-2-[1-(pent-4-en-1-yl)-1H-indazole-3-car-
boxamido] butanoate (MDMB-4en-PINACA), methyl 
[1-(4-f luorobenzyl)-1H-indazole-3-carbonyl]valinate 
(MMB-FUBINACA), 5F-MDMB-PINACA and other drugs 
such as methamphetamine, N-methyl-1-(3,4-methylenedi-
oxyphenyl)propan-2-amine (MDMA) and ketamine (data not 
shown). Three out of twenty urine samples were found to 
contain only metabolites of 4F-MDMB-BINACA (Table 3). 
From these three samples, sample 2 contained only an ester 
hydrolysis metabolite (m/z 350). Both samples 1 and 3 have 
similar first four metabolites in terms of % peak area ratio 
ranking: (1) ester hydrolysis (ion detected at m/z 350, B22), 
(2) ester hydrolysis, oxidative defluorination to butanoic acid 
(ion detected at m/z 362, B4), (3) ester hydrolysis, mono-
hydroxylation (ion detected at m/z 366, B8) and (4) ester 
hydrolysis plus dehydrogenation (ion detected at m/z 348, 
B20).
Discussion
Glucosides (B7) and sulfate (B11) phase II metabolites of 
4F-MDMB-BINACA were tentatively identified in the C. 
elegans model. Glucosides and sulfate metabolites have been 
reported with other SCBs where C. elegans was employed 
as the in-vitro model [24]. Sulfate and glucuronide phase 
II metabolites of 4F-MDMB-BINACA was identified by 
Wagmann et al. [29]. However, glucuronides of 4F-MDMB-
BINACA were not observed in the C. elegans model, which 
is consistent with findings from previous studies [23, 24]. 
Rydevik et al. [33] described an easy method to generate 
endogenous glucuronide conjugates from glucosides using 
free radical tetramethylpiperidinyl-1-oxy, hence proving 
C. elegans’ relevance in mammalian phase II metabolism. 
Nevertheless, phase I metabolites are usually better marker 
metabolites compared to phase II metabolites because of 
its higher mass spectrometry responses and stability over 
time [34].
The most prevalent and abundant in-vivo metabolite was 
that derived from the hydrolysis of metabolically labile ter-
minal methyl ester moiety via a two-step reaction mecha-
nism by the carboxylesterases (CES) [35]. The finding is 
similar to that obtained by Krotulski et al. [5], Haschimi 
et al. [30] and Wagmann et al. [29]. This outcome was antici-
pated since CES-mediated hydrolysis is commonly reported 
as the major metabolic pathway among the SCBs impacting 
the terminal ester group [36]. Similar to the in-vivo find-
ings, 4F-MDMB-BINACA ester hydrolysis (B22) was the 
major metabolite for both HepG2 and HLM models, con-
sistent with the known hydrolytic activity of CES reported 
[37]. Wagmann et al. [29] established that ester hydrolysis of 
4F-MDMB-BINACA is catalysed by the CES1 isoform, in 
agreement with the preference of CES1 in metabolizing ester 
substrates that contain a small alcohol group and a bulky 
acyl group [35]. As CES constitutes the major metabolic 
pathways for the metabolism of 4F-MDMB-BINACA, inter-
individual CES1 variability due to genetic polymorphism 
cannot be overlooked [38].
Ester hydrolysis plus dehydrogenation metabolite (B20) 
was the second most abundant major metabolite in the HLM 
model, similar to the in-vivo findings where it is the second 
most prevalent metabolite detected in 18/20 urine samples 
(Table 2). Ester hydrolysis with dehydrogenation formed in-
vivo in this study was also reported among other indazole 
carboxamide type SCBs with tert-leucine methyl ester moi-
eties such as 5F-MDMB-PINACA [15] and MDMB-4en-
PINACA [39, 40]. This biotransformation was reported by 
Table 3  In-vivo urinary profile 
of individual urine samples 
that contain only 4F-MDMB-
BINACA metabolites
ID Biotransformation % Peak area ratio (ranking)
Sample 1 Sample 2 Sample 3
B22 Ester hydrolysis 100 (1) 100 (1) 100 (1)
B20 Ester hydrolysis, dehydrogenation 4.9 (4) ND 4.2 (4)
B4 Ester hydrolysis, oxidative defluorination to 
butanoic acid
12 (2) ND 6.8 (2)
B8 Ester hydrolysis, monohydroxylation
(tert-leucine)
7.4 (3) ND 5.2 (3)
B1 Ester hydrolysis,
N-dealkylation
ND ND 0.81 (7)
B18 Oxidative
defluorination
2.2 (5) ND 2.3 (6)
B2 Ester hydrolysis,
oxidative defluorination
ND ND 2.7 (5)
B17 Oxidative defluorination
to butanoic acid
0.55 (6) ND ND
B0 4F-MDMB-BINACA 0.020 ND ND
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both Krotulski et al. [5]. and Haschimi et al. [30]. However, 
it was proposed by Wagmann et al. [29] that this metabolite 
was more likely a lactone product formed after hydroxy-
lation of the tert-leucine moiety, with or without former 
ester hydrolysis of 4F-MDMB-BINACA, based upon the 
presence of fragments with m/z 320  (C17H23FN3O2+) and 
m/z 113  (C6H9O2+), a 4,4-dimethyl-2-oxotetrahydrofuran-
3-ylium ion in positive ionisation mode, which appears to 
be more easily formed from lactone, and the absence of 
these lactone metabolites in negative ionisation mode due 
to its non-ionizable nature in contrast to ionizable carbox-
ylic acids. Although this proposal sounds plausible, it is not 
without question. The presence of m/z 330  (C18H21FN3O2+) 
in their spectrum of “lactone” indicates loss of  H2O from 
the precursor ion and similarly the presence of m/z 332 
 (C18H23FN3O2+) due to loss of  H2O was observed for ester 
hydrolysis metabolite, and yet such a  H2O loss fragment ion 
was not observed for the parent molecule retaining a methyl 
ester moiety. These results suggest that this compound is 
more likely to have a carboxylic acid than an ester, which 
contradicts the aforementioned reasoning by Wagmann et al. 
[29]. The same authors also proposed lactone formation for 
the B3 and B14 metabolites. Careful examination of results 
in this study showed the presence of the ion at m/z 113 in 
very low signal intensity for B20 but not found for both B3 
and B14 product ion spectra. Moreover, B3 and B14 were 
detected in the negative ESI mode but not for B20 (Table 4). 
Based upon these findings, it appeared that both lactone and 
dehydrogenation metabolites were present, but since mass 
spectral results can be inconclusive and indeed seemed to be 
contradictory in this case, further comprehensive structural 
analysis by nuclear magnetic resonance (NMR) spectros-
copy is needed for confirmation.
Oxidative defluorination metabolite (B18), the second 
major metabolite (% peak area ratio > 10) in HLM model 
was detected as the third least prevalent metabolite in the 
in-vivo samples. Oxidative defluorination with subsequent 
butanoic acid formation (B17) metabolite, the second major 
metabolite after monohydroxylation in the C. elegans model 
was the least prevalent metabolite found among the 20 urine 
samples. Fluoro-substituted SCBs at the 5‐pentyl position 
of pentylindole/pentylindazole moiety was found to give 
rise to predominantly 5‐hydroxypentyl and 5‐pentanoic 
acid metabolites [41]. However, oxidative defluorination 
with (B17) or without further butanoic acid (B18) metabo-
lite was found only in 7 and 13 urine samples, respectively. 
The B18 metabolite was ranked third by Haschimi et al. [30], 
whilst B17 was ranked second by Krotulski et al. [5] in terms 
of relative peak area abundance. One possible explanation 
for the differences was that both Haschimi et al. [30] and 
Krotulski et al. [5] used relative peak area abundance for 
the ranking, but for this study, the metabolite prevalence 
in the urine samples was employed instead. The major in-
vitro metabolites discussed above: B22, B20, B18 and B17 
(Table 2) were also the four common metabolites identified 
among the seven most abundant metabolites for each model 
(Fig. 3 a–d), demonstrating complementary in-vitro findings 
that may assist in further streamlining the selection of suit-
able urinary marker (s).
As most of the urine samples obtained in this study were 
found to contain other SCBs’ metabolites and other drugs, 
the urinary profile of the three individual urine samples that 
encompass 4F-MDMB-BINACA metabolites exclusively 
(Table 3) is worth considering when selecting a suitable 
urinary marker. The four most abundant metabolites identi-
fied (B22, B4, B8 and B20) among the three urine samples 
almost coincided with the top four most prevalent metabo-
lites found in the 20 urine samples. This indicated that the 
phase I metabolism of 4F-MDMB-BINACA are unlikely 
to be affected significantly by polydrug intake. Wagmann 
et al. [29] identified CYP3A5, CYP3A4, CYP1A2, CYP2C8 
and CYP2C19 involvement in the phase I metabolism of 
Table 4  Product ion spectra of B3 and B14 metabolites obtained in the negative electrospray ionization mode
CE collision energy
Mass error of the precursor ion ≤ 5.00 ppm
ID RT (min) Biotransformation Precursor ion 
exact mass
[M-H]−
CE (eV) Formula Product ions






B3 5.42 Ester hydrolysis, oxidative 
defluorination to butanoic 
acid, dehydrogenation
358.1408 10 C14H14N3O3 272.1041 3.3
C7H8NO3 154.0510 2.6
C7H5N2 117.0458 4.3
B14 6.75 Ester hydrolysis, monohy-
droxylation (tert-leucine), 
dehydrogenation
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4F-MDMB-BINACA and also excluded the possibility of 
a single CYP enzyme that may impact the in-vivo biotrans-
formation of 4F-MDMB-BINACA.
It was difficult to assign a ranking to the in-vivo metabo-
lites based upon % peak area ratio because wide inter-indi-
vidual variability was observed among the metabolites. The 
% peak area abundance ratio of metabolites detected in the 
urine samples are often affected by numerous factors such 
as drug intake behaviour (intake route, amount of drug and 
intake frequency), time from last drug intake [16] and meta-
bolic stability. It should be noted that % peak area abundance 
ratios do not necessarily reflect absolute concentrations due 
to differences in ionization capacity and matrix effects bias 
for each metabolite. The exact ranking of metabolites with 
respect to their peak area abundance would require fur-
ther validated quantification of the metabolites. Moreover, 
genetic makeup, physiological conditions (age, gender and 
ethnicity), environmental influences (diet) and pathological 
factors (liver diseases, diabetes, and obesity) would further 
complicate the metabolism of drugs. Thus, identification of 
the relevant urinary markers was based primarily upon the 
prevalence of the in-vivo metabolites instead of the metabo-
lites ranking that was based upon % peak area abundance 
ratio. The urinary marker selected would also be preferably 
found in all three in-vitro models especially in the C. elegans 
model where metabolite production could be scaled up to 
allow isolation and characterization of the metabolites.
Based upon the two criteria and the above findings sug-
gested relevant in-vivo urinary markers were ester hydroly-
sis, m/z 350 (B22, in 20/20 samples) and ester hydrolysis 
followed by dehydrogenation, m/z 348 (B20, in 18/20 sam-
ples) metabolites. Ester hydrolysis with subsequent oxida-
tive defluorination to butanoic acid metabolite (m/z 362, 
B4) detected in 16/20 urine samples seemed to be a choice 
urinary marker as it appeared to have a higher % peak area 
ratio when compared to ester hydrolysis plus dehydrogena-
tion metabolite (B20). However, this metabolite was only 
detected in trace amounts in both the C. elegans and HLM 
models. Hence, structural elucidation could not be con-
firmed unless a reference standard is made available. Despite 
the relatively high % peak area ratio and detection in 16/20 
urine samples, ester hydrolysis followed by monohydroxyla-
tion at the tert-leucine moiety (m/z 366, B8) metabolite was 
not reported among the 17 urine samples from the forensic 
psychiatric ward and prison in Haschimi et al.’s study [30]. 
Hence, the use of this metabolite as the urinary marker was 
not selected.
Finally, a comparison of the results obtained from incu-
bations of 4F-MDMB-BINACA with three different models 
showed that all of them were in agreement with the tentatively 
identified urinary metabolites. C. elegans and HLM models 
detected all of the in-vivo metabolites (100%), whilst HepG2 
cells detected 7 out of the 8 in-vivo metabolites (87.5%). 
HepG2 model detected the major ester hydrolysis metabo-
lite of 4F-MDMB-BINACA in abundance but the rest of the 
metabolites were found in a small amount. This might be due 
to the low activity of numerous metabolizing enzymes result-
ing in lower drug biotransformation [42]. Comparison of C. 
elegans with in-vivo metabolites showed that while C. elegans 
has limitations such as a low abundance of ester hydrolysis 
metabolite, in general, the metabolic profiles were in good 
agreement. The findings also supported that C. elegans pos-
sessed enzymatic activity that mimics the human metabolism 
of 4F-MDMB-BINACA. HLM possessed both the CYP and 
carboxylesterase enzymes accounted for biotransformation 
that matches with the in-vivo findings. It should be noted that 
the chemical structures of the tentative elucidated metabo-
lites have not been unequivocally confirmed. With C. elegans 
model, scaling up of metabolites production for NMR spec-
troscopy could provide unequivocal structural elucidation of 
the metabolites. C. elegans has also been reported to form 
and trap active metabolites using trapping agents such as glu-
tathione [28]. Scaling up these potential active metabolites 
conjugates allows the identification of potential metabolite tox-
icities thus giving an enhanced understanding of the toxicity 
mechanism of 4F-MDMB-BINACA. Therefore, C. elegans is 
a useful complementary metabolic model for SCBs, especially 
when a larger quantity of metabolites is required.
Conclusions
The present study showed that HLM proved to be a suit-
able predictive in-vitro − in-vivo extrapolation model for 
4F-MDMB-BINACA. C. elegans demonstrated the ability to 
form all of the in-vivo metabolites and has the potential to be 
used as a complementary model to predict and characterize 
human metabolites, as well as identifying possible drug toxici-
ties for emerging SCBs. For the identification of 4F‐MDMB‐
BINACA intake, ester hydrolysis (B22) and ester hydrolysis 
followed by dehydrogenation (B20) metabolites were identi-
fied as specific and relevant urinary markers. The difficulty 
in unequivocally identifying the structures of dehydrogena-
tion metabolites including B20 by mass spectrometry demon-
strated the need to utilise NMR spectroscopy. Future work will 
include isolation and confirmation of scaled-up reactions by 
C. elegans model to confirm the proposed chemical structure 
assignments to the metabolites identified here.
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